Q2 2012 ResultsInvestor Conference Call

July 31, 2012 / Marijn Dekkers, CEO

DisclaimerThis presentation may contain forward-looking statements based on currentassumptions and forecasts made by Bayer Group or subgroup management.

Various known and unknown risks, uncertainties and other factors could lead tomaterial differences between the actual future results, financial situation,development or performance of the company and the estimates given here.These factors include those discussed in Bayer’s public reports which areavailable on the Bayer website at www.bayer.com.

The company assumes no liability whatsoever to update these forward-lookingstatements or to conform them to future events or developments.

• Investor Handout • Q2 2012Page 2

• Investor Handout • Q2 2012Page 3

2nd Quarter 2012 –Strong Operating Performance

Delivered record sales, lower reported EBIT due to high special charges but nicely improved adj. earnings

Significant positive currency effects

Strong operating momentum broadly based: HealthCare with best quarter ever CropScience at new record for 2nd quarter performance MaterialScience with record quarterly sales and highest adj.

EBITDA for a second quarter since 2007

Full year 2012 financial outlook raised significantly: 4-5% organic growth and core EPS up ~10%

• Investor Handout • Q2 2012Page 4

EBITin € million

-41%

750

1,273

Salesin € million% currency & portfolio adj.

+5%

10,1779,252

EBITDAadjusted*in € million

+7%

2,1722,035

Core EPSin €

+14%

1.471.29

*before special items

Q2’12Q2’11 Q2’12Q2’11 Q2’12Q2’11 Q2’12Q2’11

2nd Quarter 2012 –Strong Operating Performance

Regional Performance–Growth Led By USA and Emerging Economies

• Investor Handout • Q2 2012Page 5

Western Europe

-2%

~1,020

+14%

~1,510

+6%

~460

-4%~700

+10%

¹ Emerging economies include: Latin America, Asia w/o Japan, Australia,New Zealand, Africa and Middle East incl. Turkey, Eastern Europe

² Others = Japan, Australia, New Zealand, Canada³ Emerging Asia = Asia w/o Japan, Australia, New Zealand

Q2’12 Group Sales by Region Emerging EconomiesIn € million, ∆% yoy Fx adjusted

Group €10,177m; +5%

Emerging Asia³

LatinAmerica

EasternEurope

Africa & Middle East

EmergingEconomies¹

+7%

Others²+7%

USA+10%

36%

31%

22%

11%

2nd Quarter 2012 –Cash Flow And Net Debt Development

• Investor Handout • Q2 2012Page 6

+€1,060m

7.9

GCF oFCF

1,226

Invest-ments

444 925

∆ %y-o-y -20 -25

NCFcont.

1,369

-11 +49Q1´12 Q2´12

6.9

Q2’12 Cash Flow Net Debt DevelopmentCash Flow in € million, Net Debt in € billion

HealthCare –Record Operating Performance,OutlookRaised

• Investor Handout • Q2 2012Page 7*before special items

Q2’12 Sales Earnings

Pharma+10% (+4%)

ConsumerHealth

+9% (+4%)36%

HealthCare €4,628m; +10% (+4%)

2,6851,943

Price+1%

Volume+3%

Fx+6%

Portfolio0%

In € million, ∆% yoy, () = Fx & portf. adjusted

Q2‘11 Q2‘12 Q2‘11 Q2‘12

722 809

434 439

+12%

+1%

1,1561,248 +8%

335 -1%

837902 +8%

502

331

Adj.EBITDA*

Adj.EBIT*

571 +14%

CropScience –Strong Momentum Continues, Outlook Raised

• Investor Handout • Q2 2012Page 8

Crop Protection+18% (+14%)

EnvironmentalScience

+2% (-4%)

*before special items

BioScience+22% (+21%)

Q2’12 Sales Earnings In € million, ∆% yoy, () = Fx & portf. adjusted

CropScience €2,276m; +17% (+13%)

Price+2%

Volume+11%

Fx+5%

Portfolio-1%

1,850237

Q2‘11 Q2‘12 Q2‘11 Q2‘12

471

549 +17%

353

435 +23%

Adj.EBITDA*

Adj.EBIT*

189

MaterialScience –Further Improved

• Investor Handout • Q2 2012Page 9 **CAS: Coatings, Adhesives, Specialties*** IO: Industrial Operations

Polyurethanes+13% (+7%)

Polycarbonates-4% (-10%)

CAS**+3% (+3%)

Q2’12 Sales Earnings In € million, ∆% yoy, () = Fx & portf. adjusted

*before special items

MaterialScience €2,962m; +6% (+2%)

Price+1%

Volume+1%

Fx+5%

Portfolio-1%

1,547728

IO***+15% (+10%)

Q2‘11 Q2‘12 Q2‘11 Q2‘12

Adj.EBITDA*

Adj.EBIT*

372 385 +3%

236 232 -2%507

180

Fiscal 2012 –Group Outlook Raised Significantly

• Investor Handout • Q2 2012Page 10

2011 ∆ vs. 2010

2012EOriginal

2012EActual

Sales €36.5bn +6% ~3% or~€37bn

4-5% to €39-40bn*

Adj. EBITDA €7.6bn +7% Slightly improve High single-digit % increase

Core EPS €4.83 +15% Slightly improve ~10%

*Assuming Fx rates end of Q2’2012Outlook depends on specific planning assumptions as detailed in the Annual/Quarterly Report

Sales ∆ Fx & portf. adjusted, EBITDA before special items

Fiscal 2012 –Guidance By Subgroup

• Investor Handout • Q2 2012Page 11

HealthCareRaised:Sales to increase 3% to 4%.Adj. EBITDA to grow by mid- to high-single-digit percentage.

PharmaRaised:Sales to increase slightly.Adj. EBITDA to grow mid-single-digit percentage.

Consumer Health

Raised:Sales to increase mid-single-digit percentage.Adj. EBITDA to grow high-single-digit percentage.

CropScienceRaised:Sales to increase by ~10%.Adj. EBITDA to grow by ~20%.

MaterialScience

Unchanged:Sales and adj. EBITDA to remain level with prior year.

Q3’12: Aspire to achieve sales and adj. EBITDA on good Q2’12 level.

Sales ∆ Fx & portf. adjusted, EBITDA before special itemsOutlook depends on specific planning assumptions as detailed in the Annual/Quarterly Report

Q2 2012 ResultsInvestor Conference Call

July 31, 2012 / Marijn Dekkers, CEO